Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
© 2021. The Author(s)..
The global supply of COVID-19 vaccines remains limited. An understanding of the immune response that is predictive of protection could facilitate rapid licensure of new vaccines. Data from a randomized efficacy trial of the ChAdOx1 nCoV-19 (AZD1222) vaccine in the United Kingdom was analyzed to determine the antibody levels associated with protection against SARS-CoV-2. Binding and neutralizing antibodies at 28 days after the second dose were measured in infected and noninfected vaccine recipients. Higher levels of all immune markers were correlated with a reduced risk of symptomatic infection. A vaccine efficacy of 80% against symptomatic infection with majority Alpha (B.1.1.7) variant of SARS-CoV-2 was achieved with 264 (95% CI: 108, 806) binding antibody units (BAU)/ml: and 506 (95% CI: 135, not computed (beyond data range) (NC)) BAU/ml for anti-spike and anti-RBD antibodies, and 26 (95% CI: NC, NC) international unit (IU)/ml and 247 (95% CI: 101, NC) normalized neutralization titers (NF50) for pseudovirus and live-virus neutralization, respectively. Immune markers were not correlated with asymptomatic infections at the 5% significance level. These data can be used to bridge to new populations using validated assays, and allow extrapolation of efficacy estimates to new COVID-19 vaccines.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Nature medicine - 27(2021), 11 vom: 27. Nov., Seite 2032-2040 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Feng, Shuo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 03.12.2021 Date Revised 21.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41591-021-01540-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331301628 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331301628 | ||
| 003 | DE-627 | ||
| 005 | 20240222091124.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41591-021-01540-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1301.xml |
| 035 | |a (DE-627)NLM331301628 | ||
| 035 | |a (NLM)34588689 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Feng, Shuo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.12.2021 | ||
| 500 | |a Date Revised 21.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a The global supply of COVID-19 vaccines remains limited. An understanding of the immune response that is predictive of protection could facilitate rapid licensure of new vaccines. Data from a randomized efficacy trial of the ChAdOx1 nCoV-19 (AZD1222) vaccine in the United Kingdom was analyzed to determine the antibody levels associated with protection against SARS-CoV-2. Binding and neutralizing antibodies at 28 days after the second dose were measured in infected and noninfected vaccine recipients. Higher levels of all immune markers were correlated with a reduced risk of symptomatic infection. A vaccine efficacy of 80% against symptomatic infection with majority Alpha (B.1.1.7) variant of SARS-CoV-2 was achieved with 264 (95% CI: 108, 806) binding antibody units (BAU)/ml: and 506 (95% CI: 135, not computed (beyond data range) (NC)) BAU/ml for anti-spike and anti-RBD antibodies, and 26 (95% CI: NC, NC) international unit (IU)/ml and 247 (95% CI: 101, NC) normalized neutralization titers (NF50) for pseudovirus and live-virus neutralization, respectively. Immune markers were not correlated with asymptomatic infections at the 5% significance level. These data can be used to bridge to new populations using validated assays, and allow extrapolation of efficacy estimates to new COVID-19 vaccines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Phillips, Daniel J |e verfasserin |4 aut | |
| 700 | 1 | |a White, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Sayal, Homesh |e verfasserin |4 aut | |
| 700 | 1 | |a Aley, Parvinder K |e verfasserin |4 aut | |
| 700 | 1 | |a Bibi, Sagida |e verfasserin |4 aut | |
| 700 | 1 | |a Dold, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Fuskova, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Gilbert, Sarah C |e verfasserin |4 aut | |
| 700 | 1 | |a Hirsch, Ian |e verfasserin |4 aut | |
| 700 | 1 | |a Humphries, Holly E |e verfasserin |4 aut | |
| 700 | 1 | |a Jepson, Brett |e verfasserin |4 aut | |
| 700 | 1 | |a Kelly, Elizabeth J |e verfasserin |4 aut | |
| 700 | 1 | |a Plested, Emma |e verfasserin |4 aut | |
| 700 | 1 | |a Shoemaker, Kathryn |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Kelly M |e verfasserin |4 aut | |
| 700 | 1 | |a Vekemans, Johan |e verfasserin |4 aut | |
| 700 | 1 | |a Villafana, Tonya L |e verfasserin |4 aut | |
| 700 | 1 | |a Lambe, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Pollard, Andrew J |e verfasserin |4 aut | |
| 700 | 1 | |a Voysey, Merryn |e verfasserin |4 aut | |
| 700 | 0 | |a Oxford COVID Vaccine Trial Group |e verfasserin |4 aut | |
| 700 | 1 | |a Adlou, Syed |e investigator |4 oth | |
| 700 | 1 | |a Allen, Lauren |e investigator |4 oth | |
| 700 | 1 | |a Angus, Brian |e investigator |4 oth | |
| 700 | 1 | |a Anslow, Rachel |e investigator |4 oth | |
| 700 | 1 | |a Asselin, Marie-Claude |e investigator |4 oth | |
| 700 | 1 | |a Baker, Natalie |e investigator |4 oth | |
| 700 | 1 | |a Baker, Philip |e investigator |4 oth | |
| 700 | 1 | |a Barlow, Thomas |e investigator |4 oth | |
| 700 | 1 | |a Beveridge, Amy |e investigator |4 oth | |
| 700 | 1 | |a Bewley, Kevin R |e investigator |4 oth | |
| 700 | 1 | |a Brown, Phillip |e investigator |4 oth | |
| 700 | 1 | |a Brunt, Emily |e investigator |4 oth | |
| 700 | 1 | |a Buttigieg, Karen R |e investigator |4 oth | |
| 700 | 1 | |a Camara, Susana |e investigator |4 oth | |
| 700 | 1 | |a Charlton, Sue |e investigator |4 oth | |
| 700 | 1 | |a Chiplin, Emily |e investigator |4 oth | |
| 700 | 1 | |a Cicconi, Paola |e investigator |4 oth | |
| 700 | 1 | |a Clutterbuck, Elizabeth A |e investigator |4 oth | |
| 700 | 1 | |a Collins, Andrea M |e investigator |4 oth | |
| 700 | 1 | |a Coombes, Naomi S |e investigator |4 oth | |
| 700 | 1 | |a Clemens, Sue Ann Costa |e investigator |4 oth | |
| 700 | 1 | |a Davison, Melanie |e investigator |4 oth | |
| 700 | 1 | |a Demissie, Tesfaye |e investigator |4 oth | |
| 700 | 1 | |a Dinesh, Tanya |e investigator |4 oth | |
| 700 | 1 | |a Douglas, Alexander D |e investigator |4 oth | |
| 700 | 1 | |a Duncan, Christopher J A |e investigator |4 oth | |
| 700 | 1 | |a Emary, Katherine R W |e investigator |4 oth | |
| 700 | 1 | |a Ewer, Katie J |e investigator |4 oth | |
| 700 | 1 | |a Felle, Sally |e investigator |4 oth | |
| 700 | 1 | |a Ferreira, Daniela M |e investigator |4 oth | |
| 700 | 1 | |a Finn, Adam |e investigator |4 oth | |
| 700 | 1 | |a Folegatti, Pedro M |e investigator |4 oth | |
| 700 | 1 | |a Fothergill, Ross |e investigator |4 oth | |
| 700 | 1 | |a Fraser, Sara |e investigator |4 oth | |
| 700 | 1 | |a Garlant, Harriet |e investigator |4 oth | |
| 700 | 1 | |a Gatcombe, Laura |e investigator |4 oth | |
| 700 | 1 | |a Godwin, Kerry J |e investigator |4 oth | |
| 700 | 1 | |a Goodman, Anna L |e investigator |4 oth | |
| 700 | 1 | |a Green, Christopher A |e investigator |4 oth | |
| 700 | 1 | |a Hallis, Bassam |e investigator |4 oth | |
| 700 | 1 | |a Hart, Thomas C |e investigator |4 oth | |
| 700 | 1 | |a Heath, Paul T |e investigator |4 oth | |
| 700 | 1 | |a Hill, Helen |e investigator |4 oth | |
| 700 | 1 | |a Hill, Adrian V S |e investigator |4 oth | |
| 700 | 1 | |a Jenkin, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Kasanyinga, Mwila |e investigator |4 oth | |
| 700 | 1 | |a Kerridge, Simon |e investigator |4 oth | |
| 700 | 1 | |a Knight, Chanice |e investigator |4 oth | |
| 700 | 1 | |a Leung, Stephanie |e investigator |4 oth | |
| 700 | 1 | |a Libri, Vincenzo |e investigator |4 oth | |
| 700 | 1 | |a Lillie, Patrick J |e investigator |4 oth | |
| 700 | 1 | |a Marinou, Spyridoula |e investigator |4 oth | |
| 700 | 1 | |a McGlashan, Joanna |e investigator |4 oth | |
| 700 | 1 | |a McGregor, Alastair C |e investigator |4 oth | |
| 700 | 1 | |a McInroy, Lorna |e investigator |4 oth | |
| 700 | 1 | |a Minassian, Angela M |e investigator |4 oth | |
| 700 | 1 | |a Mujadidi, Yama F |e investigator |4 oth | |
| 700 | 1 | |a Penn, Elizabeth J |e investigator |4 oth | |
| 700 | 1 | |a Petropoulos, Christos J |e investigator |4 oth | |
| 700 | 1 | |a Pollock, Katrina M |e investigator |4 oth | |
| 700 | 1 | |a Proud, Pamela C |e investigator |4 oth | |
| 700 | 1 | |a Provstgaard-Morys, Samuel |e investigator |4 oth | |
| 700 | 1 | |a Rajapaska, Durga |e investigator |4 oth | |
| 700 | 1 | |a Ramasamy, Maheshi N |e investigator |4 oth | |
| 700 | 1 | |a Sanders, Katherine |e investigator |4 oth | |
| 700 | 1 | |a Shaik, Imam |e investigator |4 oth | |
| 700 | 1 | |a Singh, Nisha |e investigator |4 oth | |
| 700 | 1 | |a Smith, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Snape, Matthew D |e investigator |4 oth | |
| 700 | 1 | |a Song, Rinn |e investigator |4 oth | |
| 700 | 1 | |a Shrestha, Sonu |e investigator |4 oth | |
| 700 | 1 | |a Sutherland, Rebecca K |e investigator |4 oth | |
| 700 | 1 | |a Thomson, Emma C |e investigator |4 oth | |
| 700 | 1 | |a Turner, David P J |e investigator |4 oth | |
| 700 | 1 | |a Webb-Bridges, Alice |e investigator |4 oth | |
| 700 | 1 | |a Wrin, Terri |e investigator |4 oth | |
| 700 | 1 | |a Williams, Christopher J |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Nature medicine |d 1995 |g 27(2021), 11 vom: 27. Nov., Seite 2032-2040 |w (DE-627)NLM074659804 |x 1546-170X |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2021 |g number:11 |g day:27 |g month:11 |g pages:2032-2040 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41591-021-01540-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2021 |e 11 |b 27 |c 11 |h 2032-2040 | ||